Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is undergoing a period of accelerated transformation, with various technical paths available, including invasive, semi-invasive, and non-invasive methods, each with its own advantages in signal quality, safety, and operational difficulty [5][19] - The Chinese brain-computer interface market is projected to grow significantly, with the market size reaching approximately 1.73 billion yuan in 2023, accounting for 12.5% of the global market [6] - The industry is supported by a three-pronged policy approach focusing on planning, payment, and standards, which is expected to facilitate rapid development [6][33] Summary by Sections 1. Brain-Computer Interface Overview - BCI is a multidisciplinary technology that integrates neuroscience, computer science, and engineering to enable communication between the brain and external devices [17] - The technology operates through a closed-loop system involving signal input, processing, device control, and feedback [17] 2. Policy Support for BCI Development - The Chinese government has issued several policies to support the BCI industry, including the "Implementation Opinions on Promoting the Innovation and Development of the Brain-Computer Interface Industry" which outlines goals for 2027 and 2030 [6][43] - The policies aim to establish a robust industrial ecosystem, enhance innovation capabilities, and promote clinical applications of BCI technologies [43][44] 3. Technological Advancements and Applications - Core technological breakthroughs are occurring in the upstream segment of the BCI industry, particularly in hardware such as electrodes and chips [7] - The medical application of BCI is predominant, with 56% of the market share in 2023, focusing on various therapeutic areas including cognitive disorders and movement disabilities [7][9] - Companies like Lepu Medical and Aipeng Medical are actively involved in developing deep brain stimulation (DBS) technologies, with some preparing for IPOs [7][8] 4. Investment Recommendations - The report suggests focusing on both invasive and non-invasive BCI products, with specific companies identified as beneficiaries based on their clinical trial progress and commercialization potential [8] - Notable companies include Aipeng Medical and Lepu Medical for invasive products, and Xiangyu Medical and Innovation Medical for non-invasive products [8]

Market Performance - The Shanghai Composite Index reached a new high since July 3, 2015, at 4061.12 points on January 6, with overall market trading activity being robust, as the combined trading volume of the Shanghai and Shenzhen markets exceeded 1 trillion yuan shortly after 10 AM [1] Sector Performance - The metal, insurance, and brokerage sectors showed significant gains, with Huayin Securities (002945) hitting the daily limit, and Huashan Securities (600909) rising over 9%. Other securities firms such as Northeast Securities, Huatai Securities, and Caida Securities also experienced upward movement [1] Concept Trends - The brain-computer interface concept continued its strong performance from the previous day, with related indices rising over 4%. Stocks like Aipeng Medical (300753), Xiangyu Medical, Meihao Medical (301363), and Innovation Medical (002173) reached their daily limits [3] - According to a report by Open Source Securities, the brain-computer interface industry is in a high-growth phase driven by technological breakthroughs, policy support, and expectations of robotic ecosystem collaboration [3] Solid-State Battery Developments - On January 5, Finnish electric mobility technology company Donut Lab announced it would debut the world's first commercially viable solid-state battery at the 2026 CES, emphasizing that it is now ready for production [3] - Guangfa Securities noted that solid-state batteries have entered the pilot production stage, with equipment manufacturers benefiting from industrial breakthroughs, and some companies have already shipped related equipment and are collaborating with downstream clients for process validation [3]

| 名称 | 序号 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | 上证指数 | 1 | 4069.38 | 45.96 | 1.14% | | 深证成指 | 2 | 13940.24 | 111.61 | 0.81% | | 科创综指 | 3 | 1713.58 | 17.74 | 1.05% | | 万得全A | 4 | 6611.54 | 73.60 | 1.13% | | 创业板指 | 5 | 3293.18 | -1.37 | -0.04% | | 北证50 | 6 | 1479.07 | 12.65 | 0.86% | | 沪深300 | 7 | 4772.17 | 54.42 | 1.15% | | 中证500 | 8 | 7766.29 | 115.09 | 1.50% | | 中证800 | O | 5279.36 | 65.13 | 1.25% | | 中证1000 | 10 | 7821.96 | 68.08 | 0.88% | 人脑工程概念股大爆发，多股连续20%涨停。有色金属概念股早间集体走强，个股大涨。 1月6日早盘，A股继续 ...

非银金融板块盘中快速拉升，其中被视为"牛市旗手"或"市场风向标"的券商股强劲上行，华林证券（002945）冲上涨停，华安证券（600909）、东北证券 等多股大涨。 | < ロ | 券商指数(886054) 11968.03 392.47 +3.39% | | | O | | --- | --- | --- | --- | --- | | 资料 | 资讯 成分 | | 相关基金 | 月度收益 | | 华林证券 | | 17.84 | 9.99% | 0.00% | | 002945.SZ | | | | | | 华安证券 | | 7.58 | 9.70% | -0.26% | | 600909.SH | | | | | 1月6日，沪指高开高走，截至午盘收盘，沪指涨1.14%，创十年新高。深成指涨0.81%，创业板指跌0.04%。沪深两市半日成交额1.8万亿，较上个交易日放 量1455亿，全市场近3700只个股上涨。 | 上证指数 | 深证成指 | 科创综指 | | --- | --- | --- | | 4069.38 | 13940.24 | 1713.58 | | +45.96 +1.14% +111.6 ...

本报记者 刘钊 1月6日开盘，A股脑机接口概念板块延续强势，多只个股快速封板。截至记者发稿，其中伟思医疗（688580.SH）、三 博脑科（301293）（301293.SZ)、翔宇医疗（688626.SH）、爱朋医疗（300753）（300753.SZ)、美好医疗（301363） （301363.SZ）等多只个股20cm涨停，麦澜德（688273.SH）、诚益通（300430）（300430.SZ）、熵基科技 （301330）（301330.SZ）、博拓生物（688767.SH）等多只个股涨幅居前。 | 물을 | 代码 | 名称 | | 最新 | 涨幅% ↓ | 涨跌 | 成交量 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 688580 | 伟思医疗 | 1 | 69.70 | 20.01 | 11.62 | 8.70万 | | 2 | 301293 | 三博脑科 | 1 | 84.94 | 20.01 | 14.16 | 2.63万 | | 3 | 688626 | 翔宇医疗 | 1 | 87.12 | 20.00 | 14.52 | ...

Core Viewpoint - The medical ETF (512170) has shown significant performance, with a daily increase of over 5% and reaching a 20-day high, indicating strong market interest and potential growth in the healthcare sector [1]. Group 1: ETF Performance - The medical ETF opened high on January 6 and saw a peak increase of over 1%, with a trading volume exceeding 350 million yuan [1]. - The ETF has recorded five consecutive days of gains, reflecting a robust upward trend in the healthcare sector [1]. Group 2: Component Stocks - Brain-computer interface stocks, specifically Sanbo Brain Science and Meihua Medical, both hit the daily limit up of 20%, marking two consecutive days of gains [1]. - Conversely, the CXO sector experienced a pullback, with Tigermed seeing a decline of over 1% [1]. Group 3: Market Insights - Tesla CEO Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices in 2026, which could accelerate the commercialization of this technology [2]. - The National Medical Products Administration of China held a meeting to expedite the review and approval of related medical devices, indicating regulatory support for the industry [2]. Group 4: Industry Outlook - CITIC Securities highlighted that China's brain-computer interface technology is relatively advanced globally, which may lead to the emergence of leading companies in this field and enhance valuations in the secondary market [3]. - Zhongtai Securities noted a potential rebound in the pharmaceutical sector after four years of decline, driven by the realization of innovative drug export logic and industry recovery due to policy reforms [3].

Core Insights - The medical device sector is experiencing a strong upward trend, with the CSI All Index Medical Device Index rising by 1.25% and significant gains in key stocks such as Meihua Medical and Xiangyu Medical [1] - Neuralink, owned by Elon Musk, plans to begin large-scale production of brain-machine interface devices in 2026, aiming for a streamlined and automated surgical process [1] - The brain-machine interface has been included in China's 14th Five-Year Plan, with specific goals for technological breakthroughs by 2027 and industry strength by 2030 [1] Market Performance - The medical device ETF (159883) has seen a 1.16% increase, with net subscriptions exceeding 400 million units [1] - The latest net inflow into the medical device ETF is 274 million yuan [1] Industry Developments - Domestic high-end medical device market share is increasing, with over 70% penetration of domestic DR and ultrasound diagnostic equipment in grassroots medical institutions [2] - The brain-machine interface industry is expected to enter a growth phase, transitioning from research to commercialization, supported by policy and technological advancements [2] - The brain-machine interface market is projected to grow at a CAGR of 17% from 2025 to 2034, reaching an estimated $12.4 billion by 2034 [2] ETF Insights - The medical device ETF (159883) has the highest brain-machine interface content in the market, accounting for over 23% of its holdings, and focuses on innovative domestic companies [3] - The Hong Kong medical ETF (159366) tracks a medical theme index, providing exposure to high-quality assets in the medical device sector, including minimally invasive brain science and robotics [3]

Group 1 - The medical ETF (512170) opened high on January 6, rising over 1% and reaching a 20-day high, with real-time transaction volume exceeding 350 million yuan. The ETF recorded a daily increase of over 5%, marking five consecutive days of gains [1][5] - Brain-computer interface stocks, including Sanbo Brain Science and Meihua Medical, both hit the 20% daily limit up, achieving two consecutive boards. Conversely, the CXO sector saw a pullback, with Tigermed falling over 1% [1][5] Group 2 - On January 5, 2026, Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices, advancing the commercialization of the technology. Concurrently, the National Medical Products Administration held a meeting to expedite the review and approval of related medical devices [3][6] - According to CITIC Securities, China's brain-computer interface technology is relatively advanced globally, with potential to cultivate leading companies in the sector. This could enhance the valuations of related listed companies in the secondary market and stimulate financing in the primary market, creating a synergy between capital and industry development [7] - Zhongtai Securities noted that the pharmaceutical sector is expected to rebound in 2025 after four consecutive years of decline, driven by the realization of innovative drug export logic and industry recovery post-policy reform. Certain areas of the medical device sector may also see a reversal of difficulties [7]

北京商报讯（记者 丁宁）1月6日，延续前一交易日大涨走势，人脑工程板块涨幅明显。 具体来看，三博脑科、美好医疗开盘"20cm"涨停，爱朋医疗、翔宇医疗等高开超10%。 ...

据交易所数据显示， 美好医疗连续两个交易日涨停，晋级2连板。该股今日于9：25封涨停，成交额0.57 亿元，换手率0.44%。金融界App AI线索挖掘：近期 脑机接口领域技术突破消息引发市场关注，政策层 面亦推动脑机接口成为新的经济增长点，该公司被市场归类为脑机接口概念相关标的，受此影响获得市 场关注。 风险提示：连板股波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等公开 数据生成，内容不构成投资建议。） ...